All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @phumeza.tshevu on TikTok · 58s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @phumeza.tshevu's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Small rainy, more rainy, more rain.
  2. 0:03So today the con, okay, my daily make-up date, first week here, was then the day.
  3. 0:10So my daily time, the day side effects, then I got one.
  4. 0:14And I didn't want to do a catch up because I'm gabooning to, because I got a leash number one.
  5. 0:21But in the near future, I feel lighter.
  6. 0:24I feel lighter.
  7. 0:25I feel lighter.
  8. 0:26I feel lighter.
  9. 0:29So, since I lost my soul, I've been in the world, and since the update may be monthly.
  10. 0:36I've been in the update monthly, I've been in the world since I was born with a big group of people.
  11. 0:41Why are you a sampek?
  12. 0:43Because I was born with a big group of people who were born with a big group of people who were born with a big group.
  13. 0:52But I'm not a big group.
  14. 0:55Bye, bye-bye.

Ozempic journey updates: what TikTok gets right and wrong

Phumeza Tshevu

TikTok creator

16.3K viewsWatch on TikTok

Quick answer

The creator reports feeling lighter during week one of Ozempic use and mentions experiencing one side effect, though she does not name it or specify her dose. Early subjective sensations of lightness on semaglutide are consistent with the drug's known mechanisms of appetite suppression and delayed gastric emptying, rather than measurable fat loss, which typically requires several weeks of titrated dosing. GI side effects including nausea affect up to 44% of semaglutide users in clinical trials, making their acknowledgment clinically relevant even in informal update content.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Ozempic journey updates: what TikTok gets right and wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Ozempic journey updates: what TikTok gets right and wrong" from Phumeza Tshevu. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator reports feeling lighter during week one of Ozempic use and mentions experiencing one side effect, though she does not name it or specify her dose.

The reason this review is not generic is the source wording and the canonical claim label "glp1 xhosanation tiktoksa mantshingilane inimba semi update on oz." In this clip, the useful excerpt is: "Small rainy, more rainy, more rain." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Early sensations of lightness on Ozempic are most likely driven by appetite suppression and delayed gastric emptying, not fat reduction, per Drucker (2022, Nature Reviews Drug Discovery).
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator reports feeling lighter during week one of Ozempic use and mentions experiencing one side effect, though she does not name it or specify her dose.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator reports feeling lighter during week one of Ozempic use and mentions experiencing one side effect, though she does not name it or specify her dose. Early subjective sensations of lightness on semaglutide are consistent with the drug's known mechanisms of appetite suppression and delayed gastric emptying, rather than measurable fat loss, which typically requires several weeks of titrated dosing. GI side effects including nausea affect up to 44% of semaglutide users in clinical trials, making their acknowledgment clinically relevant even in informal update content.
  • Wilding et al. (2021, NEJM) found average weight loss of 14.9% over 68 weeks on 2.4mg semaglutide, meaning week-one feelings are not predictive of final outcomes.
  • Early sensations of lightness on Ozempic are most likely driven by appetite suppression and delayed gastric emptying, not fat reduction, per Drucker (2022, Nature Reviews Drug Discovery).

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Wilding et al. (2021, NEJM) found average weight loss of 14.9% over 68 weeks on 2.4mg semaglutide, meaning week-one feelings are not predictive of final outcomes.
  • Early sensations of lightness on Ozempic are most likely driven by appetite suppression and delayed gastric emptying, not fat reduction, per Drucker (2022, Nature Reviews Drug Discovery).
  • Nausea affects roughly 44% of semaglutide users in clinical trials, making side effects in week one statistically common, not unusual.
  • Sodhi et al. (2023, JAMA) linked GLP-1 agonists used for weight loss to elevated risks of pancreatitis and gastroparesis compared to other weight-loss drugs, a risk worth discussing with a provider before starting.
  • Semaglutide is typically titrated from 0.25mg weekly before reaching therapeutic doses, meaning week-one experience reflects the lowest pharmacological exposure in the entire treatment course.
  • Compounded semaglutide products are not equivalent to FDA-approved formulations like Ozempic or Wegovy and are subject to different regulatory standards.
  • Personal TikTok update videos, including this one, are not a substitute for individualized medical advice from a licensed provider who knows your full health history.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @phumeza.tshevu actually say?

Honestly, this transcript is difficult to parse. The audio quality and translation challenges mean we're working with fragments: she mentions "side effects," says she "got one," and repeats "I feel lighter" several times. She also references a monthly update schedule and hints at a community or social context around her Ozempic use. That's roughly the full content of what came through clearly.

What we can reasonably extract: she's in her first week on Ozempic, she experienced at least one side effect, and she subjectively feels lighter. She did not specify her dose, her starting weight, her diagnosis, or what the side effect actually was. This is a personal update video, not a medical explainer, and it should be read accordingly. The claims are thin, but they're also mostly just personal experience, which is a different category of risk than someone dispensing medical advice.

Does the science back this up?

Feeling lighter in week one of semaglutide is plausible, but probably not because of fat loss. It's more likely a combination of reduced appetite, lower food volume in the gut, and a bit of placebo effect. Real weight loss on Ozempic takes weeks to become measurable.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed an average 14.9% body weight reduction over 68 weeks at the 2.4mg dose, but the trajectory in the first weeks is slow. Early perceived lightness is often tied to reduced bloating and lower caloric intake rather than actual fat reduction. A 2022 review by Drucker in Nature Reviews Drug Discovery confirmed that GLP-1 receptor agonists suppress appetite primarily through central nervous system pathways and delayed gastric emptying, both of which can produce a subjective sense of feeling lighter almost immediately. So she's not wrong to feel it. She's just probably misidentifying the cause.

What did they get wrong (or right)?

She didn't get much wrong, mostly because she didn't claim much. That's actually somewhat responsible for a TikTok health video. She didn't promise a specific number of kilograms lost, didn't recommend a dose, and didn't tell anyone else to start Ozempic. Credit where it's due.

The one area worth flagging: she mentions a side effect but doesn't name it. For a platform with 16,000 viewers, that's a missed opportunity to be useful, and it could also be quietly normalizing the idea that side effects are minor and not worth discussing. Ozempic's GI side effects, specifically nausea, vomiting, and diarrhea, affect a significant portion of users. The STEP trials reported nausea in roughly 44% of participants (Wilding et al., 2021, NEJM). Glossing over side effects in week-one content can set unrealistic expectations for new users who then feel blindsided when their experience is rougher.

What should you actually know?

Week one on semaglutide is not representative of the full experience. The drug is titrated slowly, meaning most people start at 0.25mg weekly and don't reach therapeutic doses for months. Early feelings of lightness are real but are driven by appetite suppression and gut slowdown, not meaningful fat loss.

Side effects are common and worth taking seriously. A 2023 analysis by Sodhi et al. in JAMA found that GLP-1 receptor agonists used for weight loss were associated with significantly higher risks of pancreatitis, gastroparesis, and bowel obstruction compared to bupropion-naltrexone. These are not common outcomes, but they are real ones. Anyone starting Ozempic should be doing so under medical supervision, with regular follow-up, not based on a TikTok update. Compounded semaglutide products, which are increasingly available online, are not equivalent to FDA-approved branded formulations and carry their own regulatory and safety considerations.

Bottom line on this video

This is a low-risk personal update from someone sharing their early Ozempic experience. The claims are vague enough that there's not much to debunk. The feeling of lightness in week one is plausible and physiologically explainable. The bigger concern isn't what she said, it's what she didn't say: side effects deserve more than a passing mention, and first-week feelings are a poor predictor of the full journey ahead. If you're considering GLP-1 therapy based on content like this, talk to a licensed provider who can review your full medical history before you start.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Phumeza Tshevu · TikTok creator

16.3K views on this video

#xhosanation #tiktoksa #mantshingilane #inimba semi update on ozempic journey🤔☺️

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about wilding et al. (2021, nejm) found average weight loss of?

Wilding et al. (2021, NEJM) found average weight loss of 14.9% over 68 weeks on 2.4mg semaglutide, meaning week-one feelings are not predictive of final outcomes.

What does the video say about early sensations of lightness on ozempic?

Early sensations of lightness on Ozempic are most likely driven by appetite suppression and delayed gastric emptying, not fat reduction, per Drucker (2022, Nature Reviews Drug Discovery).

What does the video say about nausea affects roughly 44% of semaglutide users in clinical trials,?

Nausea affects roughly 44% of semaglutide users in clinical trials, making side effects in week one statistically common, not unusual.

What does the video say about sodhi et al. (2023, jama) linked glp-1 agonists used for?

Sodhi et al. (2023, JAMA) linked GLP-1 agonists used for weight loss to elevated risks of pancreatitis and gastroparesis compared to other weight-loss drugs, a risk worth discussing with a provider before starting.

What does the video say about semaglutide?

Semaglutide is typically titrated from 0.25mg weekly before reaching therapeutic doses, meaning week-one experience reflects the lowest pharmacological exposure in the entire treatment course.

What does the video say about compounded semaglutide products?

Compounded semaglutide products are not equivalent to FDA-approved formulations like Ozempic or Wegovy and are subject to different regulatory standards.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Phumeza Tshevu, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.